Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Cellectis S.A. ALCLS.PA
$1.63
-$0.11 (-6.79%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
97382818.00000000
-
week52high
4.25
-
week52low
1.68
-
Revenue
19171000
-
P/E TTM
-1
-
Beta
2.06106800
-
EPS
-1.71000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 14:00
Описание компании
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Рекомендации
аналитиков
Рекомендации аналитиков
Grading company | New grade | Previous grade | Recommendation date |
---|---|---|---|
Barclays | Overweight | Overweight | 13 мая 2022 г. |
Wells Fargo | Equal-Weight | Overweight | 06 янв 2022 г. |
JMP Securities | Market Outperform | 30 ноя 2021 г. | |
Baird | Neutral | Outperform | 08 окт 2021 г. |
Guggenheim | Neutral | Buy | 28 апр 2021 г. |
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Свежие комментарии
Свежие комментарии